+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years - 45Years
FEMALE
ID05912517

Evaluating Nipocalimab Versus Placebo in Pregnant Women at Risk for Severe Hemolytic Disease of the Fetus and Newborn A Phase 3 Randomized, Double-Blind Study

Led by Janssen Research & Development, LLC · Updated on 2026-11-03

120

Participants Needed

69

Research Sites

113 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the use of nipocalimab in pregnant individuals at risk for severe Hemolytic Disease of the Fetus and Newborn HDFN. The study aims to compare nipocalimab with a placebo to see if it can reduce the risk of fetal anemia, a condition where the babys red blood cell levels drop too low during pregnancy. This phase 3, randomized, placebo-controlled, and triple-blind study is conducted across multiple centers. Participants will receive either nipocalimab or a matching placebo through weekly intravenous infusions starting from randomization until 35 weeks of gestational age. The study groups include an experimental group receiving nipocalimab and a placebo group receiving an inactive treatment, both administered once weekly. The study timeline spans from randomization during weeks 13 to 18 of pregnancy through delivery and includes follow-up through the neonatal period and beyond. Participants will undergo various assessments including lab tests, fetal DNA testing, and monitoring of maternal and neonatal health outcomes. Researchers will measure the percentage of pregnancies without fetal loss, intrauterine transfusions, hydrops fetalis, or neonatal death, among many other maternal and infant health parameters. Follow-up extends to 104 weeks for some infant assessments, including growth and development, while maternal safety and pregnancy complications are also monitored up to 24 weeks postpartum. This comprehensive monitoring aims to capture the effect of nipocalimab on both mother and baby throughout pregnancy and after birth.

CONDITIONS

Brief Title

A Study of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn (HDFN)

Research Team

S

Study Contact

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here